晚间公告丨9月24日这些公告有看头

Group 1 - Yong'an Pharmaceutical plans to acquire 49.2% equity of its subsidiary Ling'an Technology for 27 million yuan, aiming for full control to enhance management and accelerate business expansion in the creatine sector [3] - Dongfang Materials received an administrative regulatory decision from the China Securities Regulatory Commission, requiring rectification of accounting and internal control issues within 30 days, but it will not affect daily operations [4] - Zhongwei Semiconductor submitted an application for H-share issuance to the Hong Kong Stock Exchange, marking a step towards listing on the main board [5] - Kangtai Biological's application for a flu virus split vaccine has been accepted by the National Medical Products Administration, which could enhance the company's product portfolio and market position if approved [6] - Jialiqi intends to transfer 35% equity of Xi'an Junhui Aviation Technology to a related party for 20.87 million yuan, resulting in no remaining stake in the company [7] Group 2 - Jinma Leisure's chairman completed a share reduction plan, selling 3.83 million shares, which accounts for 2.43% of the company's total equity [9] - Heng Rui Medicine signed a licensing agreement for the drug Rukang Trastuzumab, with potential milestone payments up to 1.093 billion USD, enhancing its overseas market presence [11] - Linyang Energy won a procurement project from the State Grid worth approximately 142 million yuan, expected to positively impact the company's performance in 2025 and 2026 [12] - Sinopec Oilfield Services' subsidiary signed a contract worth 359 million USD for a project in Iraq, which is projected to contribute 3.15% to the company's 2024 revenue [13]